Strict embargo: 00.01hrs Friday 14 December, 2012


The number of people diagnosed with thyroid cancer in England has doubled since the early 1990s, according to a new data briefing* published by the National Cancer Intelligence Network (NCIN) today (Friday).

Between 1990 and 1994 around 900 people (1.7 per 100,000 people) were diagnosed with thyroid cancer every year in England. By 2006-10 this figure increased to 1,950 (3.4 per 100,000 people). But, thanks to effective treatments, survival rates have remained high, at around 90 per cent.

Researchers from the Oxford Cancer Intelligence Unit found that most of this increase has been seen in a particular type of thyroid cancer called papillary cancer. This form of the disease has the best prognosis.

The rise has been linked to increased diagnosis of the disease through better techniques such as ultrasound and fine needle biopsies that can pick up much smaller cancers and possibly a ‘real’ rise in the number of people developing thyroid cancer.

Mr David Chadwick, consultant endocrine surgeon at Chesterfield Royal Hospital and Chair of the NCIN Thyroid Working Group, said: “The exact reason behind this steep rise in thyroid cancer cases remains unclear. We now have more sensitive diagnostic techniques so it could be that more cancers are being picked up when patients are being tested for other conditions. And, this could mean that we're detecting and treating some cancers that would otherwise not have shown up during a person's life. “We may also be seeing a ‘real’ increase in the incidence of thyroid cancer, some of which may be due to improved long-term survival of other cancers previously treated with radiotherapy to the neck or chest. Sadly, older forms of radiotherapy had a side-effect that increased the risk of other cancers later in life.”

The report also showed that thyroid cancer is three times more common in women than in men**. For men and women one year survival rates had increased, by nine per cent for men to 88.3 per cent and by 15 per cent for women to 94.3 per cent. Unlike most cancers, thyroid cancer is most often picked up in people aged between 20 and 59, particularly for the papillary form of the disease, with those aged 30 and 54 having the highest rates.

Treatment for thyroid cancer most commonly includes surgery to remove the thyroid and is often followed up with radioactive iodine. This acts as a ‘targeted treatment’ as the iodine is only taken up by thyroid cancer cells, ultimately killing them.

While this treatment approach has meant that most people with thyroid cancer are successfully treated, there are some forms of the disease that have a very poor prognosis. Currently, it is difficult for doctors to predict the behaviour of thyroid cancer in an individual patient, which means that most patients will require thyroid surgery.

Chris Carrigan, head of the National Cancer Intelligence Network (NCIN), said: “This increase in the number of people being diagnosed with thyroid cancer reflects a trend that we’re seeing in other countries. While thyroid cancer is generally a very treatable disease, there is a lot we don’t understand about it. We need to better understand the different forms of the disease so that doctors can predict which patients need more aggressive treatment and which don’t.”


For media enquiries please contact Simon Shears on 020 3469 8054 or, out-of-hours, the duty press officer on 07050 264 059.

Notes to editors:

* These figures are from the NCIN briefing ‘Thyroid cancer – trends by sex, age and histological type’ and will be available from the NCIN website: **There was an average of 671 cases diagnosed in women compared with 233 for men in 1990-94 in England. These numbers had increased to 1427 and 521, respectively (2006-10)

About the National Cancer Intelligence Network (NCIN)

  • The NCIN was established in June 2008 and its remit is to coordinate the collection, analysis and publication of comparative national statistics on diagnosis, treatment and outcomes for all types of cancer
  • Under the umbrella of the National Cancer Research Institute, the NCIN aims to promote efficient and effective data collection at each stage of the cancer journey
  • Patient care will be monitored by the NCIN through expert analyses of up-to-date statistics
  • The NCIN will drive improvements in the standards of care and clinical outcomes through exploiting data
  • The NCIN will support audit and research programmes by providing cancer information

The National Cancer Intelligence Network will be part of Public Health England from 1 April 2013